DSC Advisors’s VYNE Therapeutics VYNE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $1.31M | Hold |
696,465
| – | – | 11.93% | 3 |
|
|
2024
Q2 | $1.37M | Hold |
696,465
| – | – | 4.58% | 5 |
|
|
2024
Q1 | $2.14M | Hold |
696,465
| – | – | 3.42% | 7 |
|
|
2023
Q4 | $1.62M | Buy |
696,465
+581,465
| +506% | +$1.35M | 2.68% | 7 |
|
|
2023
Q3 | $460K | Hold |
115,000
| – | – | 0.59% | 11 |
|
|
2023
Q2 | $467K | Hold |
115,000
| – | – | 0.7% | 9 |
|
|
2023
Q1 | $354K | Buy |
115,000
+27,778
| +32% | +$85.6K | 0.31% | 10 |
|
|
2022
Q4 | $236K | Sell |
87,222
-61,111
| -41% | -$165K | 0.54% | 12 |
|
|
2022
Q3 | $596K | Hold |
148,333
| – | – | 0.61% | 27 |
|
|
2022
Q2 | $1.04M | Hold |
148,333
| – | – | 1.04% | 17 |
|
|
2022
Q1 | $1.74M | Buy |
148,333
+6,611
| +5% | +$77.4K | 0.6% | 14 |
|
|
2021
Q4 | $2.6M | Buy |
141,722
+80,611
| +132% | +$1.48M | 2.01% | 8 |
|
|
2021
Q3 | $1.53M | Hold |
61,111
| – | – | 1.55% | 12 |
|
|
2021
Q2 | $3.86M | Buy |
61,111
+3,436
| +6% | +$217K | 2.79% | 9 |
|
|
2021
Q1 | $7.11M | Hold |
57,675
| – | – | 4.4% | 5 |
|
|
2020
Q4 | $6.56M | Hold |
57,675
| – | – | 5.42% | 6 |
|
|
2020
Q3 | $6.89M | Sell |
57,675
-2,867
| -5% | -$343K | 4.61% | 6 |
|
|
2020
Q2 | $7.54M | Buy |
60,542
+31,712
| +110% | +$3.95M | 8.27% | 5 |
|
|
2020
Q1 | $5.56M | Buy |
+28,830
| New | +$5.56M | 5.43% | 6 |
|